Gene Editing Reduces Cholesterol Levels

• Gene editing reduces cholesterol levels by 50%
• The study involved 15 participants with high cholesterol
• The ANGPTL3 gene is the target for editing using CRISPR

The research, presented on October 8, 2025, at the annual conference of the American Heart Association in New Orleans, showed that editing a single gene could potentially lower dangerously high levels of cholesterol and triglycerides in the blood. In the context of a clinical trial phase 1, in which 15 patients participated, they examined the safety of the new therapy based on CRISPR.

Along with previous results, the gene editing therapy reduced the level of low-density lipoprotein (LDL) cholesterol and triglycerides by approximately 50%. This effect could potentially reduce the risk of cardiovascular events throughout life.

The study found that LDL levels decreased by 48.9% and triglycerides by 55.2% observed just two months after treatment. This therapy targets the ANGPTL3 gene, responsible for regulating cholesterol levels in the body.

Scientists hope that this therapy will become an alternative to traditional medication, such as statins, which need to be taken daily. However, the long-term safety of this method remains in question, and further research will be necessary to confirm its effectiveness and safety.

Tags: Research